<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303940</url>
  </required_header>
  <id_info>
    <org_study_id>050239</org_study_id>
    <secondary_id>05-C-0239</secondary_id>
    <secondary_id>NCI-P6672</secondary_id>
    <secondary_id>CDR0000462620</secondary_id>
    <nct_id>NCT00303940</nct_id>
    <nct_alias>NCT00261885</nct_alias>
  </id_info>
  <brief_title>Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors</brief_title>
  <official_title>A Phase I Trial and Pharmacokinetic Study of Talabostat (PT-100, Val-Boro-Pro) in Combination With Temozolomide or Carboplatin in Pediatric Patients With Relapsed or Refractory Solid Tumors Including Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Talabostat may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as temozolomide and carboplatin,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving talabostat together with temozolomide or carboplatin may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of talabostat when&#xD;
      given together with temozolomide or carboplatin in treating young patients with relapsed or&#xD;
      refractory brain tumors or other solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the dose of talabostat, when used in combination with either temozolomide or&#xD;
           carboplatin, at which maximum plasma dipeptidyl peptidase IV enzyme inhibition is&#xD;
           achieved (in the absence of talabostat-related dose-limiting toxicity) in pediatric&#xD;
           patients with refractory or relapsed solid tumors, including brain tumors.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of talabostat, when used in combination with&#xD;
           temozolomide or carboplatin in pediatric patients, if dose-limiting toxicity attributed&#xD;
           to talabostat is observed.&#xD;
&#xD;
        -  Define the toxicity profile of talabostat when used in combination with temozolomide or&#xD;
           carboplatin.&#xD;
&#xD;
        -  Describe the pharmacokinetic profile of talabostat in pediatric patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Study levels, at baseline and after drug administration, of serum cytokines (interleukin&#xD;
           [IL]-2, IL-6, IL-10, filgrastim [G-CSF], tumor necrosis factor-α, IL-1β, IL-8, IP10, and&#xD;
           thrombospondin) that may be important in the immune-mediated antitumor effect of&#xD;
           talabostat.&#xD;
&#xD;
        -  Evaluate the antitumor effect of talabostat in combination with temozolomide or&#xD;
           carboplatin on pediatric solid tumors by direct assessment of tumor response.&#xD;
&#xD;
        -  Study the effect of talabostat on neutrophil function.&#xD;
&#xD;
        -  Evaluate the expression of fibroblast activation protein (FAP) in pediatric tumors using&#xD;
           immunohistochemistry to detect FAP in paraffin-embedded tissue sections from existing&#xD;
           tumor specimens, when available.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of talabostat. Patients are stratified according to&#xD;
      tumor histology and prior therapy.&#xD;
&#xD;
      Based on stratification, patients receive either oral temozolomide on days 1-5 or carboplatin&#xD;
      IV over 30 minutes on days 1-2. Patients also receive oral talabostat on days 7-20. Treatment&#xD;
      repeats every 28 days in the absence of disease progression or unacceptable toxicity. (Closed&#xD;
      to accrual as of 5/25/2009)&#xD;
&#xD;
      Cohorts of 2-6 patients receive escalating doses of talabostat until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or &lt;&#xD;
      4 of 12 patients experience dose-limiting toxicity during the first course of therapy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 26 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Childhood Germ Cell Tumor</condition>
  <condition>Kidney Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Neuroblastoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>talabostat mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumors, including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Rhabdomyosarcoma and other soft tissue sarcomas&#xD;
&#xD;
               -  Ewing's sarcoma family of tumors&#xD;
&#xD;
               -  Osteosarcoma&#xD;
&#xD;
               -  Neuroblastoma&#xD;
&#xD;
               -  Wilms' tumor&#xD;
&#xD;
               -  Hepatic tumors&#xD;
&#xD;
               -  Germ cell tumors&#xD;
&#xD;
               -  Primary brain tumors&#xD;
&#xD;
                    -  In patients with brainstem or optic gliomas, requirement for histological&#xD;
                       confirmation can be waived if biopsy was not performed&#xD;
&#xD;
                         -  Patients with brainstem gliomas that did not respond to therapy but&#xD;
                            that are without radiographic evidence of disease progression must have&#xD;
                            clinical evidence of progression&#xD;
&#xD;
                    -  Patients with brain tumors must be on stable or tapering dose of&#xD;
                       corticosteroids for 7 days prior to study entry&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Relapsed or failed to respond to frontline curative therapy, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Surgery&#xD;
&#xD;
               -  Radiotherapy&#xD;
&#xD;
               -  Chemotherapy&#xD;
&#xD;
               -  Combination of modalities&#xD;
&#xD;
          -  No other potentially curative treatment options available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8 mg/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3 (platelet transfusion independent)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGPT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min OR age-adjusted creatinine* as follows:&#xD;
&#xD;
               -  No more than 0.8 mg/dL (for patients ≤ 5 years of age)&#xD;
&#xD;
               -  No more than 1.0 mg/dL (for patients 6 to 10 years of age)&#xD;
&#xD;
               -  No more than 1.2 mg/dL (for patients 11 to 15 years of age)&#xD;
&#xD;
               -  No more than 1.5 mg/dL (for patients &gt; 15 years of age) NOTE: *For patients&#xD;
                  receiving carboplatin a nuclear glomerular filtration rate study, 24-hour urine&#xD;
                  collection, and serum creatinine for estimation of creatinine clearance is&#xD;
                  required if under 15 years of age OR serum creatinine and weight for estimation&#xD;
                  of creatinine clearance is required if 15-18 years of age&#xD;
&#xD;
          -  Patients with history of seizures eligible if seizures controlled by anticonvulsants&#xD;
&#xD;
          -  No clinically significant, unrelated systemic illness, including either of the&#xD;
             following:&#xD;
&#xD;
               -  Serious infections&#xD;
&#xD;
               -  Hepatic, renal, or other organ dysfunction that would preclude study treatment&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No generalized pitting peripheral edema&#xD;
&#xD;
          -  No sensitivity to valine-proline boronic acid&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered to ≤ grade 1 from the acute toxic effects of all prior chemotherapy,&#xD;
             immunotherapy, or radiotherapy prior to study entry&#xD;
&#xD;
          -  Any number of prior chemotherapy regimens allowed&#xD;
&#xD;
          -  Prior temozolomide or carboplatin as frontline therapy or in the adjuvant setting&#xD;
             allowed provided patient did not experience severe toxicities related to the drug and&#xD;
             tumor progressed during this therapy&#xD;
&#xD;
          -  At least 3 weeks since last dose of all myelosuppressive chemotherapy&#xD;
&#xD;
          -  At least 7 days since last dose of anticancer biologic agents (e.g., retinoids)&#xD;
&#xD;
          -  At least 30 days since prior investigational agents&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy to &gt; 25% of marrow-containing bones (pelvis,&#xD;
             spine, or skull) (2 weeks for palliative [limited-port] radiotherapy)&#xD;
&#xD;
          -  At least 2 months since prior autologous stem cell transplantation and recovered&#xD;
&#xD;
          -  At least 1 week since prior filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa&#xD;
&#xD;
          -  At least 2 weeks since prior pegfilgrastim&#xD;
&#xD;
          -  No history of allogeneic stem cell transplantation&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy, radiation therapy, or immunotherapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holly Meany, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Fox, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Meany H, Balis FM, Aikin A, Whitcomb P, Murphy RF, Steinberg SM, Widemann BC, Fox E. Pediatric phase I trial design using maximum target inhibition as the primary endpoint. J Natl Cancer Inst. 2010 Jun 16;102(12):909-12. doi: 10.1093/jnci/djq174. Epub 2010 May 11.</citation>
    <PMID>20460632</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>recurrent Wilms tumor and other childhood kidney tumors</keyword>
  <keyword>recurrent childhood malignant germ cell tumor</keyword>
  <keyword>recurrent childhood liver cancer</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>childhood malignant ovarian germ cell tumor</keyword>
  <keyword>childhood malignant testicular germ cell tumor</keyword>
  <keyword>childhood teratoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

